Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products!
Request a FREE sample of our GMP products!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
GDF15 mAb - 01 | PCC | Metabolism | Solid tumor,Cancer cachexia |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CEA-C077 | Human | ClinMax™ Human GDF-15 ELISA Kit | |||
GD5-H81Q3 | Human | Biotinylated Human GDF-15 / MIC-1 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
EP-164 | Human | GDF15 [Biotinylated] : GFRAL Inhibitor Screening ELISA Kit | |||
GD5-M5149 | Mouse | Mouse GDF-15 / MIC-1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
GD5-H82F9 | Human | Biotinylated Human GDF-15 / MIC-1 Protein, Avitag™, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
GD5-C5148 | Cynomolgus | Cynomolgus GDF-15 / MIC-1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
GD5-H5269 | Human | Human GDF-15 / MIC-1 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
GD5-H5149 | Human | Human GDF-15 / MIC-1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Mouse GDF-15, His Tag (Cat. No. GD5-M5149) at 1 μg/mL (100 μL/well) can bind Human GFR alpha-like, Fc Tag (Cat. No. GFE-H5259) with a linear range of 0.3-10 ng/mL (QC tested).
The purity of Biotinylated Human GDF-15, Avitag, Fc Tag (Cat. No. GD5-H82F9) is more than 85% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NGM-120 | NGM-120 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Anorexia; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Cachexia; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Visugromab | CTL-002 | Phase 2 Clinical | CatalYm GmbH | Solid tumours; Urinary Bladder Neoplasms | Details |
Ponsegromab | PF-06946860 | Phase 2 Clinical | Pfizer Inc | Ovarian Neoplasms; Heart Failure; Fatigue; Pancreatic Neoplasms; Anorexia; Feeding and Eating Disorders; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung | Details |
GDF15 agonist (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus | Details | |
NN-9215 | Human-GDF15; MIC-1; NN-9215; LA-GDF15 | Phase 1 Clinical | Novo Nordisk A/S | Obesity | Details |
CIN-109 | CIN-109; JNJ-9090 | Phase 1 Clinical | Janssen Sciences Ireland Unlimited Company | Obesity | Details |
AV-380 | AV-380 | Phase 1 Clinical | Aveo Pharmaceuticals Inc | Cachexia | Details |
This web search service is supported by Google Inc.